{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-032672","form_type":"8-K","ticker":"TVGN","cik":"0001860871","company_name":"Tevogen Bio Holdings Inc.","filed_at":"2023-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.856320+00:00","generated_at":"2026-06-10T17:55:36.095328+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Semper Paratus files S-4 for merger with Tevogen Bio; expects close near end of 2023","bullets":["Filed Registration Statement on Form S-4 with SEC for proposed business combination with Tevogen Bio.","Combined company to be named Tevogen Bio Holdings Inc., expected to trade on NYSE American as TVGN/TVGNW.","Transaction approved by both boards; closing subject to SEC review, shareholder approval, and other conditions.","Tevogen Bio is a clinical-stage immunotherapy company developing off-the-shelf T cell therapies in virology, oncology, neurology."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-032672","json":"https://secwatch.observer/filing/0001493152-23-032672.json","markdown":"https://secwatch.observer/filing/0001493152-23-032672.md","text":"https://secwatch.observer/filing/0001493152-23-032672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223032672/0001493152-23-032672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860871/000149315223032672/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T17:55:36.095328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}